Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality

Recruiting Phase 4 Interventional Study
Helicobacter Pylori Infections Atrophic Gastritis Gastric Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 – 64
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Prevention
Participants needed
30,000 (estimated)
Sponsor
International Agency for Research on Cancer · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Currently no ideal preventive modalities are available for reducing gastric-cancer caused mortality in organized population-based application. The primary objective of the study is to determine if H.pylori screening followed by eradication of positive subjects and endoscopic follow-up of those with serological evidence of atrophic gastritis reduces mortality from gastric cancer in middle-aged peop…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Men and women aged 40-64 at the time of signing the consent form * Willingness to get involved in the study irrespective in which of the study arms (after detailed information on the potential benefits and risks that this study may confer) * The person has signed a consent for…
Contacts

Marcis Leja, MD, PhD

+37 1 29 49 75 00

marcis.leja@lu.lv

CONTACT

Jin Young Park, PhD

+33 4 72 73 81 63

parkjy@iarc.fr

CONTACT